Anavex Life Sciences Corp. (AVXL) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+2.3%

$1.17

vs $1.14 price

Levered DCF

$1.20

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

4.27

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-16.48×	-10.92×	-10.92×	-16.65×	-33.24×	-10.11×	-5.85×	-6.62×
P/B	8×	3.94×	3.68×	5.57×	8.31×	9.72×	7.62×	5.62×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-14.16×	-7.95×	-7.98×	-13.54×	-29.25×	-7.58×	-4.58×	-4.82×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	11.6×	8.86×	12.32×	14.95×	14.97×	4.73×	5.03×	6.26×
Debt / equity	0×	0×	0×	0×	0×	0×	0×	0×
Interest coverage	0×	0×	-57.85×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-48.9%	-35.8%	-33.5%	-33.7%	-25.1%	-96.5%	-129.6%	-85.2%
Return on invested capital	-54.2%	-44.0%	-38.4%	-1.4%	-27.8%	-82.0%	0.0%	0.0%
Return on assets	-44.7%	-31.7%	-30.8%	-31.4%	-23.5%	-76.1%	-103.8%	-71.6%
Free cash flow yield	-5.1%	-6.5%	-5.3%	-3.1%	-2.4%	-8.0%	-12.0%	-10.9%
Earnings yield	-6.1%	-9.1%	-9.1%	-6.0%	-3.0%	-9.9%	-17.0%	-15.1%
Enterprise value	$656.5M	$341.9M	$371.6M	$644.6M	$1.1B	$235.5M	$132.4M	$92.3M
Net debt / EBITDA	2.21×	3.07×	3.24×	3.13×	4.04×	0.94×	0.77×	1.2×
Cash conversion cycle (days)	0	0	0	0	0	0	0	0